



Cyclacel Pharmaceuticals to present at the 13th Annual BIO CEO & Investor Conference

Berkeley Heights, NJ, February 1, 2011 –Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”) today announced that the Company will present at the 13th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Tuesday, February 15, 2011 at 9:00 a.m. Eastern in the Conrad Room. Cyclacel’s presentation will be webcast live and archived for 90 days on the Corporate Presentations page of the Cyclacel website at www.cyclacel.com.

In addition, Mr. Rombotis will be a panelist at a Therapeutic Workshop entitled “Oncology: Lung Cancer - Clearing the Airways on New Treatments” taking place on Monday, February 14, 2011 at 9:00 a.m. Eastern in the Jade Room. More information can be obtained at: <http://www.bio.org/bioceo/program/lung-cancer-clearing-airways.aspx>.

About the BIO CEO & Investor Conference

Now in its thirteenth year, the BIO CEO & Investor Conference is the largest independent investor conference for the life sciences industry focused on publicly-traded biotechnology companies. The meeting provides a forum where institutional investors, industry analysts, and executives from leading global pharmaceutical and biotechnology companies will discuss investment opportunities in the biotechnology industry. This year’s meeting will feature issues-oriented plenary sessions, company presentations, one-on-one meetings and educational sessions focused on current business trends in the life sciences.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 3 development for the treatment of acute myeloid leukemia in the elderly under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, and is in Phase 2 studies for myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact for Cyclacel Pharmaceuticals, Inc.

Investors/Media:

Corey Sohmer, (908) 517-7330
csohmer@cyclacel.com

© Copyright 2011 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel[®] are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn[®] and Xclair[®] are trademarks of Sinclair Pharma plc.